Eye Drug's Success With Diabetic Macular Degeneration

| Sep 20, 2013

A drug traditionally used to treat age-related macular degeneration has been successful in also treating diabetic macular edema in recent trials.

According to Bayer, which co-developed the drug along with Regeneron, the drug VEGF Trap-Eye, also known as Eylea, has reached goals established by the companies during year-long, Phase 3 trials.

Diabetic macular edema, which impacts about 10 percent of those with diabetes, leads to leaking blood vessels that cause swelling of the retina and resulting blurred vision. It is traditionally treated with lasers that are used to seal fluid leaks.

Eylea is currently used to treat neovascular (also known as wet) age-related macular degeneration, which is caused by the leaking of blood and fluid into the retina, leading to distortion and loss of vision.

The drug is administered through monthly injections.

Regeneron plans to seek approval to market the drug in the United States sometime later this year, about a year earlier than initially intended.

According to the American Academy of Ophthalmology, in addition to diabetic macular edema, those with diabetes are also at a higher risk of diabetic retinopathy, glaucoma, and retinal detachment.

For optimum eye health, the organization recommends annual comprehensive eye exams, maintaining low blood sugar levels to prevent damage to blood vessels in the eyes, keeping blood pressure and cholesterol levels in check, getting plenty of exercise, and not smoking.

Click Here To View Or Post Comments

Categories: Bayer, Diabetic Retinopathy, Eylea, Glaucoma, Macular Degeneration, Macular Edema, Regeneron, Retinal Detachment

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Username: Password:
©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.